Using PSMA PET scans to improve prostate cancer treatment accuracy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 multicenter randomized controlled trial aims to evaluate the effectiveness of second generation PSMA PET imaging in accurately staging unilateral prostate cancer compared to standard MRI and biopsy methods. Eligible participants will be randomly assigned to receive either a PSMA PET scan or no further imaging before undergoing focal therapy. The study seeks to determine if PSMA PET can enhance diagnostic precision, thereby reducing the risk of residual or recurrent disease after treatment. The focus is on men diagnosed with localized prostate carcinoma who are candidates for focal therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age \> 50
2. Clinical stage \< T2b
3. PSA \< 15
4. Combined targeted and systematic MRI-guided biopsy shows unilateral Gleason Grade Group 2 or 3 prostate cancer

Exclusion Criteria:

1. Unable to obtain consent
2. Weight \>250 kg (weight limitation of scanners)
3. Unable to lie flat for 30 minutes to complete the PET imaging
4. Lack of intravenous access
5. eGFR \< 40 mL/min/1.73 m2 and/or a history of a severe reaction to CT contrast
6. Prior androgen deprivation therapy or radiation therapy to prostate gland

Where it's running

• Prostate Cancer Centre
  Calgary, Alberta, Canada Recruiting
• Royal Alexandra Hospital
  Edmonton, Alberta, Canada Recruiting
• University of Alberta Hospital
  Edmonton, Alberta, Canada Recruiting
• Princess Margaret Cancer Centre
  Toronto, Ontario, Canada Recruiting

Study contacts

• Study coordinator: Adam Kinnaird, MD, PhD
• Email: ask@ualberta.ca
• Phone: (780) 407-5800

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer

  This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07650240

• MRI-based microboost SBRT with de-escalated whole-gland radiation for localized prostate cancer

  This study tests whether giving a focused 45 Gy microboost to MRI-defined lesions with smaller whole-gland doses (30 or 35 Gy) is safe and effective for men with low- to intermediate-risk localized prostate cancer.

  Recruiting Phase 2 Georgetown University · Washington D.C., District of Columbia · NCT07644598

• Short-term hormone therapy with PSMA PET/CT before prostate removal for high-risk localized prostate cancer

  This trial will test whether giving short-term androgen-deprivation therapy (ADT) before prostate removal lowers PSMA PET signal and helps predict recurrence risk in men with localized high-risk prostate cancer.

  Recruiting Phase 2 Baptist Health South Florida · Miami, Florida · NCT07455903

• Comparing Lutetium-177 and Actinium-225 PSMA-targeted radiation before prostatectomy

  This will test whether giving one of two PSMA-targeted radiation drugs (Lutetium-177 or Actinium-225) before prostate removal works differently in men with high or very high-risk localized prostate cancer.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT07054346

• Two-fraction radiotherapy for localized prostate cancer

  This study is testing if giving radiotherapy in just two sessions instead of five can effectively treat localized prostate cancer while causing fewer side effects for patients.

  Recruiting UMC Utrecht · Utrecht · NCT06518226

• Magnetic resonance imaging with hyperpolarized bicarbonate to measure tissue pH in localized prostate cancer

  This small pilot study tests whether injecting hyperpolarized 13C bicarbonate before MRI can safely map tissue pH in men with localized prostate cancer.

  Recruiting Early Phase 1 University of California, San Francisco · San Francisco, California · NCT05851365

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.